Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

Mostrar otras versiones (1)

BACKGROUND: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C J, Pollak, M N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039819/
https://www.ncbi.nlm.nih.gov/pubmed/21102589
http://dx.doi.org/10.1038/sj.bjc.6605972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039819/
https://www.ncbi.nlm.nih.gov/pubmed/21102589
http://dx.doi.org/10.1038/sj.bjc.6605972

Ejemplares similares